^
    over3years
    [VIRTUAL] The Intrinsic Limitation and Clinical Impact of Mutant Allele - Specific Real - Time PCR - Based EGFR Mutation Assay in NSCLC (IASLC-WCLC 2021)
    Two patients (EGFR A763_Y764insFQEA and EGFR T751_I759>S) had received erlotinib during their treatment course and both of them showed stable disease with a progression-free survival of 5.9 and 10.1 months, respectively...The most overlooked mutations were exon 20 insertions. A comprehensive EGFR mutation assay can provide significant benefit to NSCLC patients, especially in an area with a high prevalence of EGFR mutations.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR A763_Y764insFQEA • EGFR exon 20 mutation • EGFR T751_I759>S
    |
    FoundationOne® CDx • cobas® EGFR Mutation Test v2
    |
    erlotinib